This company is no longer active
BELLUS Health Toekomstige groei
Future criteriumcontroles 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for BELLUS Health.
Belangrijke informatie
46.1%
Groei van de winst
41.4%
Groei van de winst per aandeel
Biotechs winstgroei | 34.9% |
Inkomstengroei | 69.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 16 Jun 2023 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2025 | 40 | -147 | -110 | -64 | 3 |
12/31/2024 | 0 | -141 | -130 | -127 | 3 |
12/31/2023 | 0 | -117 | -125 | -101 | 2 |
3/31/2023 | 0 | -87 | -89 | -89 | N/A |
12/31/2022 | 0 | -76 | -77 | -77 | N/A |
9/30/2022 | 0 | -73 | -68 | -68 | N/A |
6/30/2022 | 0 | -71 | -64 | -64 | N/A |
3/31/2022 | 0 | -70 | -60 | -60 | N/A |
12/31/2021 | 0 | -71 | -61 | -61 | N/A |
9/30/2021 | 0 | -64 | -49 | -49 | N/A |
6/30/2021 | 0 | -47 | -40 | -40 | N/A |
3/31/2021 | 0 | -37 | -36 | -36 | N/A |
12/31/2020 | 0 | -32 | -30 | -30 | N/A |
9/30/2020 | 0 | -34 | -30 | -30 | N/A |
6/30/2020 | 0 | -35 | -32 | -32 | N/A |
3/31/2020 | 0 | -33 | -29 | -29 | N/A |
12/31/2019 | 0 | -26 | -21 | -21 | N/A |
9/30/2019 | 0 | -18 | -14 | -14 | N/A |
6/30/2019 | 0 | -14 | -9 | -9 | N/A |
3/31/2019 | 0 | -9 | -8 | -8 | N/A |
12/31/2018 | 0 | -7 | -7 | -7 | N/A |
9/30/2018 | 0 | -6 | -7 | -7 | N/A |
6/30/2018 | 0 | -5 | -6 | -6 | N/A |
3/31/2018 | 0 | -4 | -5 | -5 | N/A |
12/31/2017 | 0 | -1 | -5 | -3 | N/A |
9/30/2017 | 0 | -1 | -4 | -3 | N/A |
6/30/2017 | 1 | 0 | -3 | -2 | N/A |
3/31/2017 | 1 | 0 | -3 | -2 | N/A |
12/31/2016 | 1 | -2 | N/A | -2 | N/A |
9/30/2016 | 3 | -1 | N/A | -2 | N/A |
6/30/2016 | 3 | 0 | N/A | -2 | N/A |
3/31/2016 | 3 | 0 | N/A | -2 | N/A |
12/31/2015 | 3 | 0 | N/A | -2 | N/A |
9/30/2015 | 2 | 0 | N/A | -2 | N/A |
6/30/2015 | 2 | -1 | N/A | -2 | N/A |
3/31/2015 | 2 | -1 | N/A | -2 | N/A |
12/31/2014 | 2 | -2 | N/A | -3 | N/A |
9/30/2014 | 2 | -2 | N/A | -3 | N/A |
6/30/2014 | 2 | -1 | N/A | -4 | N/A |
3/31/2014 | 2 | -1 | N/A | -3 | N/A |
12/31/2013 | 2 | -1 | N/A | -3 | N/A |
9/30/2013 | 2 | -1 | N/A | -3 | N/A |
6/30/2013 | 2 | -2 | N/A | -3 | N/A |
3/31/2013 | 2 | -10 | N/A | -3 | N/A |
12/31/2012 | 2 | -13 | N/A | -3 | N/A |
9/30/2012 | 3 | -15 | N/A | -2 | N/A |
6/30/2012 | 3 | -14 | N/A | -2 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 0A4U is forecast to remain unprofitable over the next 3 years.
Winst versus markt: 0A4U is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: 0A4U is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: 0A4U's revenue (69% per year) is forecast to grow faster than the UK market (4.5% per year).
Hoge groei-inkomsten: 0A4U's revenue (69% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if 0A4U's Return on Equity is forecast to be high in 3 years time